Plasmablastic Lymphoma: A Review of Current Knowledge and Future DirectionsReportar como inadecuado

Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

RETRACTED This article has been retracted as it was found to contain a substantial amount of material from the following published article: “Plasmablastic Lymphoma: A Systematic Review” by Jorge J. Castillo and John L. Reagan, in The Scientific World Journal.

Advances in Hematology - Volume 2015 2015, Article ID 315289, 11 pages -

Review Article

Department of Pathology and Blood Bank, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia

Department of Hematology, Theodor Bilharz Research Institute, Egypt

Hematopathology Division, Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia

Department of Oncology, Prince Sultan Military Medical City, Saudi Arabia

Received 16 May 2015; Revised 29 July 2015; Accepted 3 August 2015

Academic Editor: Elvira Grandone

Copyright © 2015 Ghaleb Elyamany et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Plasmablastic lymphoma PBL is an aggressive subtype of non-Hodgkin’s lymphoma NHL, which frequently arises in the oral cavity of human immunodeficiency virus HIV infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts-plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma PCM. PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone CHOP or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate-ifosfamide, etoposide, high-dose cytarabine CODOX-M-IVAC, or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin DA-EPOCH are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors CARs and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL.

Autor: Ghaleb Elyamany, Eman Al Mussaed, and Ali Matar Alzahrani



Documentos relacionados